CalebHoMD

Hematopathology, Molecular Genetics, Anatomic Pathology, Clinical Pathology

Assistant Attending, Hematopathology and Diagnostic Molecular Pathology

Dr. Ho is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Memorial Sloan Kettering Cancer CenterFellowship, Molecular Genetic Pathology, 2015 - 2016
Brigham and Women's HospitalFellowship, Hematopathology, 2014 - 2015
Yale-New Haven Medical CenterResidency, Pathology-Anatomic and Clinical, 2010 - 2014
David Geffen School of Medicine at UCLAClass of 2008

PubMed

19 citations
Tracking the evolution of therapy-related myeloid neoplasms using chemotherapy signatures.
Benjamin Diamond, Bachisio Ziccheddu, Kylee Maclachlan, Justin Taylor, Eileen Boyle
Blood. 2023-05-11
45 citations
Allogeneic haematopoietic cell transplantation impacts on outcomes of mantle cell lymphoma with TP53 alterations.
Richard J. Lin, Caleb Ho, Patrick Hilden, Juliet N. Barker, Sergio Giralt
British Journal of Haematology. 2018-12-11
17 citations
Genetic Basis of Extramedullary Plasmablastic Transformation of Multiple Myeloma.
Ying Liu, Fatima Jelloul, Yanming Zhang, Tapan Bhavsar, Caleb Ho
The American Journal of Surgical Pathology. 2020-06-01

Abstracts/Posters

Annotation of Somatic Genomic Variants in Hematologic Diseases Using OncoKB, a Precision Oncology Knowledgebase
Caleb Ho, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Long-Term Sustained Minimal Residual Disease (MRD) Negativity in Multiple Myeloma Patients Treated with Lenalidomide Maintenance Therapy: A Clinical and Correlative Ph...
Caleb Ho, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Long-Term Sustained Minimal Residual Disease (MRD) Negativity in Multiple Myeloma Patients Treated with Lenalidomide Maintenance Therapy: A Clinical and Correlative Ph...
Caleb Ho, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Weekly Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab (wKRd-D) Combination Therapy Provides Unprecedented MRD Negativity Rates in Newly Diagnosed Multiple My...
Caleb Ho, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Join now to see all

Lectures

Plasma Cell Myeloma Residual Disease Quantitation Using a Next-Generation Sequencing-Based IGH Clonal Rearrangement Assay with the Aid of a Spike-in Clonal Sequence
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
MRD-Response Driven Phase I/II Study for Newly Diagnosed Multiple Myeloma Patients Using Higher Doses of Twice-Weekly Carfilzomib (45 and 56 mg/m2) in Combination with...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018